40 results about "Duck hepatitis B virus" patented technology

The present invention provides particles for the presentation of haptens for the purpose of eliciting an immune response. The amino acid sequences of the monomers which make up the particles are derived from duck hepatitis B virus core protein. The particles may also deliver nucleic acids. The nucleic acids may be delivered for the purpose of enhancing an immune response, or for other purposes such as gene therapy.

The invention provides a small interference RNA molecule SiRNA capable of attacking human hepatitis B virus, which is double chain RNA molecule whose sequence has at least 70% of consanguinity degree with the sequence (I), wherein the antisense chain of the sequence (I) and one nucleic acid mutant has no consanguinity with the known human gene and gene expression segment. The SiRNA can be used for preparing medicament or preparation for prevention or treating hepatitis B and any diseases relating to hepatitis B viral infection.

The invention discloses a therapeutic hepatitis B vaccine. Active components of the therapeutic hepatitis B vaccine comprise a protein gp96, a hepatitis B surface antigen and a hepatitis B core protein. The protein gp96 has a sequence shown in the sequence 1 of the sequence table. The hepatitis B surface antigen has a sequence shown in the sequence 5 of the sequence table. The hepatitis B core protein has a sequence shown in the sequence 3 of the sequence table. The active components also comprise a plasmid pcDNA-gp96 containing a coding gene of the protein gp96, a plasmid pcDNA-HB containing a coding gene of the hepatitis B surface antigen and a plasmid pcDNA-HBc containing a coding gene of the hepatitis B core protein. The therapeutic hepatitis B vaccine provided by the invention can effectively inhibit hepatitis B virus (HBV) replication, can eliminate viruses infecting the liver and has a very important value to hepatitis B prevention and treatment.

The invention relates to a monoclonal antibody of hepatitis B virus X protein (HBx), which is characterized by having specificity reaction to N-end epitope or C-end epitope of HBx, but having no reaction to keyhole limpet hemocyanin (KLH) of carrier protein and other expressed proteins of hepatitis B virus (HBV). The preparation method of the monoclonal antibody comprises the steps of: fusing N-end and C-end antigen epitope polypeptides of HBx respectively with mice immunized with KLH in crosslinking way, and myeloma cells and screening to obtain the monoclonal antibody. The monoclonal antibody can be used for various immunodetection reagents and directed therapeutic drugs of HBx protein or HBx antibody and applied to diagnosis and treatment of diseases such as hepatitis b virus (HBV) infection, hepatocellular carcinoma (HCC) and the like.

An application of gentiopicroside in preparing the medicine with it in conjunction of pharmacologically acceptable carrier for suppressing HBV is disclosed. It may be tablet, capsule, powder, pill, particle, or injection.

The invention discloses a fluorescence quantitative PCR (polymerase chain reaction) detection method of duck hepatitis B virus (DHBV), and a reagent. Nucleic acid sequences in a conservative region most consistent to a DHBV Core region are used as a template to design and synthesize a primer and a fluorescent probe. A pGEM-T/DHBV Core recombinant plasmid is established to prepare a PCR standard product. A reaction system and amplification conditions are optimized. The fluorescence quantitative PCR detection method provided by the invention has the advantages of strong versatility, high sensitivity, strong specificity, good reproducibility and the like, and is suitable for detection of DHBV DNA (deoxyribonucleic acid) of different duck species in different regions.

The invention relates to an application of a phyllanthus urinaria polysaccharide component in preparing a drug for resisting a hepatitis B virus, and belongs to the field of medicine. The phyllanthus urinaria polysaccharide component is a phyllanthus urinaria polysaccharide component PUIP II which comprises rhamnose, arabinose, mannose and glucose at a molar ratio of 0.11:0.36:0.08:0.45. The phyllanthus urinaria polysaccharide component is artificially extracted, separated and purified by a medicinal plant, namely phyllanthus urinaria. An in-vitro bioactivity experiment indicates that the phyllanthus urinaria polysaccharide component PUIP II can inhibit secretion of HBsAg and HBeAg and reproduction of HBV-DNA (hepatitis B virus-deoxyribose nucleic acid) in HepG2.2.2.15 cell culture, and has a certain in-vitro HBV activity resistance effect, and an in-vivo activity experiment indicates that the PUIP II has an obvious inhibiting effect on DHBVDNA (duck hepatitis B virus deoxyribose nucleic acid) in a duck, is smaller in bounce, and can be used for preparing the drug for resisting the hepatitis B virus and for preparing health care products for protecting a liver.

The invention discloses a redback christmashush extract, and a preparation method and application thereof in preparation of drugs for treating hepatitis B. The preparation method comprises the steps of carrying out alcohol extraction, centrifugal concentration, macroporous adsorption resin column treatment, ethanol elution and reduced pressure drying, so as to obtain an effective part extract of redback christmashush. The preparation method has the beneficial effects that an extraction process is simple, convenient and reasonable; by applying the obtained effective part extract of redback christmashush in an anti-duck hepatitis B virus experiment, serum DHBV DNA can be remarkably inhibited on the seventh day and the fourteenth day (T7 and T14) by virtue of three doses of effective part extracts of redback christmashush (P is less than 0.01), and DHBV DNA rises again on fifth day (P5) after the drug delivery is stopped and is still remarkably lower than that before the drug delivery, so that the redback christmashush extract has a relatively ideal anti-hepatitis B virus effect, is a candidate drug with great promise and can be applied to the preparation of anti-hepatitis B drugs.

The invention relates to double expression plasmid of hepatitis B virus and a construction method thereof. The method comprises the following steps: firstly and respectively taking former C-C gene/self-replication regulatory element enhancer II and former S-S gene/self-replication regulatory element enhancer I of the hepatitis B virus as target genes, using eukaryotic expression vector VR012, constructing ENH II/former C-C gene vaccine recombinant plasmid VEC and ENH II/former S-S gene vaccine recombinant plasmid VES of the hepatitis B, then adopting a single primer secondary PCR method to mutate the recombinant plasmid VES and inserting restriction enzyme cutting sites into the downstream of the expression regulatory unit; and finally, using the inserted restriction enzyme cutting sites, carrying out amplification on the regulatory and expression unit of recombinant plasmid VEC by PCR, enzyme-cutting and recombining the regulatory and expression unit into mutated VES recombinant plasmid, and obtaining two starters which respectively regulate the double expression plasmid for expressing the former C-C gene and the former S-S gene of the hepatitis B virus as DNA vaccines. The recombinant HBV DNA vaccine can effectively express surface antigens and core antigens of the hepatitis B and can be used for prevention and treatment of the hepatitis B.

The invention relates to extract activity of Mallotus apelta and uses in prepartion of medicine for treating related diseases caused by hepatitis B. The extract of Mallotus apelta provided by the invention has basic components of apiolin, apiin-7-O-belta-D-glucoside, and flavonoids compounds of 5,7-dihydroxy-6-isopentene group-4'-methoxyl flavonone, flavonoids compounds Mallotus apelta have obvious inhibiting effect on hepatitis B virus surface antigen and hepatitis B virus e antigen ono surface of HepG 2215, and cabaple of inhibiting duplication of Duck Hepatitis B Virus deoxyribonucleic acid, withdraw rebound is weaker than positive reference medicine lamivudine, and hepatitis B is provided with a subsequent inhibiting effect after withdraw. The medicine according to the invention has strong function for fighting hepatitis B virus, clear active ingredient, which is suitable for industrial production, predictablly used for preparing medicine of preparing diseases infected by hepatitis B virus.

The invention discloses a recombinant polymerase isothermal amplification detection method of hepatitis B viruses in ducks, a special RPA primer pair as shown in SEQ ID No. 1 and SEQ ID No. 2 and a kit. Specific primers are designed according to the gene sequence of the duck hepatitis B viruses, and the recombinant polymerase isothermal amplification method for quickly and accurately detecting theduck hepatitis B viruses is further optimized and established. Through the method, the duck hepatitis B viruses can be detected specifically, the minimum detection template amount is 146 pg through the method, and the sensitivity is equivalent to that of traditional PCR. Since only one temperature is needed during the whole gene amplification, no special instruments and equipment are needed, theoperation is simpler and quicker, and the method and kit are suitable for on-site quick detection of the duck hepatitis B virus during production.

The present invention relates to a kind of medicinal composition for treating chronic hepatitis and its preparation process. The medicinal composition is prepared through extracting volatile oil of zedoary; water extracting astragalus root, curcuma root, etc, filtering and concentration to obtain extractum; alcohol extracting fleeceflower root, schisandra, etc, filtering and concentration to obtain extractum; merging the extractum, adding lactose, drying and crushing into fine powder; crushing aweto into fine powder; mixing fine powder, adding lactose, pelletizing, drying and spraying the volatile oil; and packing. It has determined curative effect, treating functions of benefiting vital energy, nourishing yin, removing blood stasis, etc and no toxic side effect. It is suitable for treating chronic viral hepatitis.

The invention belongs to the technical field of virus detection, and specifically relates to a LAMP (Loop-mediated Isothermal Amplification) detection reagent of DHBV (Duck Hepatitis B Virus). A specific LAMP primer is designed and synthesized according to a DHBV gene conserved region, and the specific LAMP primer comprises an upstream inner primer FIP, a downstream inner primer BIP, an upstream outer primer F3 and a downstream outer primer B3. The LAMP detection reagent is prepared from the following ingredients: a 10*Bst Buffer reaction buffer solution, dNTPs (Deoxynucleotide Triphosphates),MgSO4, Bst DNA (Deoxyribonucleic Acid) polymerase, deionized water, a color-producing reagent and the primers. The LAMP detection reagent provided by the invention has the advantages of strong specificity, high sensitivity, simpleness and convenience in operation, low cost and the like during application.

The invention discloses an application of radix gentianae in preparing a medicine for treating viral hepatitis B. The radix gentianae is a radix gentianae extract which is prepared by conducting extracting with water, ethanol or carbon dioxide as a solvent. In accordance with a conventional process, the radix gentianae or the radix gentianae extract is prepared into any one of the following pharmaceutical dosage forms: tablets, capsules, granules, pills and the like. The radix gentianae is applicable to preparation of the medicine for treating the viral hepatitis B; and the medicine, which is suitable for clinical application, is prepared from the radix gentianae. The radix gentianae can obviously reduce a DHBV-DNA titer, an HBsAg level and AST and ALT activities in serum of a hepatitis B model duck; within 7 days of drug withdrawal, a recurrence phenomenon is avoided; and in addition, the radix gentianae can relieve degeneration of hepatic cells and inflammatory cell infiltration. It is indicated that the composition (the medicine) is obvious in effect of resisting hepatitis B virus of the duck; therefore, it is indicated that the composition (the medicine) has a clinical application value. The pharmaceutical preparation of the medicine for treating the viral hepatitis B is scientific and reasonable.

The invention discloses a traditional Chinese medicine prescription for treating viral hepatitis B, and belongs to the field of traditional Chinese medicinal preparations. The traditional Chinese medicinal preparation is a pharmaceutical composition of Tibetan capillaris, radices macrotomiae, chicory herb, radix bupleuri, radix gentianae, Japanese wormwood herb and cornu saigae tataricae, and in accordance with a conventional process, the pharmaceutical composition is prepared into any one of the following pharmaceutical dosage forms: tablets, capsules, granules, pills and the like. The traditional Chinese medicinal preparation for treating the viral hepatitis B provided by the invention is scientific and reasonable in compatibility. The traditional Chinese medicinal composition can obviously reduce a DHBV-DNA titer, an HBsAg level and AST and ALT activities in serum of a hepatitis B model duck; within 7 days of drug withdrawal, a recurrence phenomenon is avoided; and in addition, the composition can relieve degeneration of hepatic cells and inflammatory cell infiltration. It is indicated that the composition is obvious in effect of resisting hepatitis B virus of the duck; therefore, it is indicated that the prescription has a clinical application value.

The invention discloses an application of radix bupleuri in preparing a medicine for treating viral hepatitis B. The radix bupleuri is a radix bupleuri extract which is prepared by conducting extracting with water, ethanol or carbon dioxide as a solvent. In accordance with a conventional process, the radix bupleuri or the radix bupleuri extract is prepared into any one of the following pharmaceutical dosage forms: tablets, capsules, granules, pills and the like. The radix bupleuri is applicable to preparation of the medicine for treating the viral hepatitis B; and the medicine, which is suitable for clinical application, is prepared from the radix bupleuri. The radix bupleuri can obviously reduce a DHBV-DNA titer, an HBsAg level and AST and ALT activities in serum of a hepatitis B model duck; within 7 days of drug withdrawal, a recurrence phenomenon is avoided; and in addition, the radix bupleuri can relieve degeneration of hepatic cells and inflammatory cell infiltration. It is indicated that the composition (the medicine) is obvious in effect of resisting hepatitis B virus of the duck; therefore, it is indicated that the composition (the medicine) has a clinical application value. The pharmaceutical preparation of the medicine for treating the viral hepatitis B is scientific and reasonable.

The invention discloses a kind of medicinal wine for treating chronic gastritis. Wind 15‑25 grams, white peony root 10‑20 grams, chicken bone grass 10‑20 grams, white back leaf root 5‑15 grams, safflower 5‑15 grams, rice wine 1000 ml, by mixing Atractylodes macrocephala, ghost needle grass, hawthorn , gallinacea, swollen joint wind, white peony root, chicken bone grass, white back leaf root, and safflower are coarsely crushed, put into a cloth bag, placed in a sealed container, soaked in rice wine, and sealed for more than 30 days to obtain. The medicated wine has the effects of invigorating the spleen and stomach, promoting qi and reducing swelling, dispelling stagnation and relieving pain, promoting blood circulation and softening the liver. gastritis; its compatibility is simplified, the source of medicine is wide, the preparation is simple and convenient, and the cost is low.

The invention discloses a monoclonal antibody capable of simultaneously recognizing a duck hepatitis A virus 1 and a duck hepatitis A virus 3, and a hybridoma cell strain and application of the monoclonal antibody. The hybridoma cell strain is high in stability and can still secrete the monoclonal antibody after subculture in vitro and frozen storage and resuscitation of cells, the secreted monoclonal antibody can simultaneously recognize the duck hepatitis A virus 1 and the duck hepatitis A virus 3, the affinity constant with the duck hepatitis A virus 1 is more than 109 according to the order of magnitudes, the monoclonal antibody does not have specific reactions with the duck viral enteritis virus, the duck hepatitis B virus, the duck tembusu virus, the goose plague virus, the riemerella anatipestifer, the escherichia coli from ducks and the salmonella anatis, so that the broad-spectrum high-specificity high-affinity detection antibody is provided for clinics and basic units to avoid leak detection of the duck hepatitis A virus 1 and the duck hepatitis A virus 3, and can be used to prepare reagents for separately detecting the duck hepatitis A virus 1 or the duck hepatitis A virus 3 and simultaneously detecting the duck hepatitis A virus 1 and the duck hepatitis A virus 3.